Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Novel in vitro booster vaccination to rapidly generate antigen-specific human monoclonal antibodies

Novel in vitro booster vaccination to rapidly generate antigen-specific human monoclonal antibodies

Thumbnail Image
Download
Name

2471.full.pdf

Size

2.77 MB

Format

Adobe PDF

Checksum (MD5)

40b017ac37e2cbcd0a9bdaed8d183bfc

Download all files submitted through automated deposit
sword-2018-05-04.original.zip (2.36 MB)
Author(s)
Sanjuan Nandin, Irene
•
Fong, Carol
•
Deantonio, Cecilia
•
Torreno-Pina, Juan A.
•
Pecetta, Simone
•
Maldonado, Paula
•
Gasparrini, Francesca
•
Kjaer, Svend
•
Borley, Daryl W.
•
Nair, Usha
more
Date Issued
July 2017
Journal
Journal of Experimental Medicine
Publisher
Rockefeller University Press
Citation
Sanjuan Nandin et al. “Novel in Vitro Booster Vaccination to Rapidly Generate Antigen-Specific Human Monoclonal Antibodies.” The Journal of Experimental Medicine 214, 8 (July 2017): 2471–2490 © 2017 Sanjuan Nandin et al
Version
Final published version
Abstract
Vaccines remain the most effective tool to prevent infectious diseases. Here, we introduce an in vitro booster vaccination approach that relies on antigen-dependent activation of human memory B cells in culture. This stimulation induces antigen- specific B cell proliferation, differentiation of B cells into plasma cells, and robust antibody secretion after a few days of culture. We validated this strategy using cells from healthy donors to retrieve human antibodies against tetanus toxoid and influenza hemagglutinin (HA) from H1N1 and newly emergent subtypes such as H5N1 and H7N9. Anti-HA antibodies were cross-reactive against multiple subtypes, and some showed neutralizing activity. Although these antibodies may have arisen as a result of previous influenza infection, we also obtained gp120-reactive antibodies from non-HIV-infected donors, indicating that we can generate antibodies without prior antigenic exposure. Overall, our novel approach can be used to rapidly produce therapeutic antibodies and has the potential to assess the immunogenicity of candidate antigens, which could be exploited in future vaccine development.
MIT Department
Institute for Medical Engineering and Science
Massachusetts Institute of Technology. Department of Chemistry
Terms of Use
Attribution 4.0 International (CC BY 4.0)
https://creativecommons.org/licenses/by/4.0/
Persistent DSpace Link
http://hdl.handle.net/1721.1/115401
DOI of Published Version
https://doi.org/10.1084/jem.20170633
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.